[1] SHEN CY, SONG YN, ZHAO Y, et al.Thoughts on Constructing Vigilance System of Chinese Medical Device in the New Era[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 697-701. [2] Eammon Hoxey. Comparison of the Articles of the European Medical Devices Directive (93/42/EEC) andthe Medical Devices Regulation (EU2017/745)[EB/OL].[2022-01-06]. https://www.bsigroup.com. [3] SHANG H, ZHANG SQ.Discussion of Enlightenment from the Reor-ganization of CDRH Regulatory for Medical Device[J]. Chinese Journal of Medical Instrumentation(中国医疗器械杂志), 2020, 44(2): 154-157. [4] ZHAO Y, LI Y, SONG YN, et al.Post-Marketing Active Monitoring of Medical Devices under Vigilance[J]. Chinese Journal of Pharma-covigilance(中国药物警戒), 2023, 20(12): 1385-1390. [5] WHO. The Importance of Pharmacovigilance (Safety Monitoring of Medicinal Products)[M]. Geneva: World Health Organization, Collabo-Rating Centre for International Drug Monitoring, 2002: 1-8. [6] YANG XY, SUN Y, TIAN CH, et al.A National Pharmacovigilance Management System in a New Era[J]. Chinese Journal of Pharma-covigilance(中国药物警戒), 2025, 22(3): 276-281, 285. [7] SHI JJ.Implementing the“Four Strictest”to Ensure Drug Safety-Interpretation of the New Version of“The People’s Republic of China Drug Administration Law”[J]. China Quality and Technical Supervision(中国质量监管), 2019(9): 22-23. [8] People’s Congress. Drug Administration Law of the People’s Republic of China[EB/OL]. (2019-08-26)[2020-05-20]. http://www.npc.gov.cn/englishnpc/c2759/c23934/202012/t20201229_384168.html. [9] WANG Q, TANG N, ZHU BC, et al.The Challenges and Reflections on Medical Device Adverse Event Monitoring in China under High-Quality Development[J]. China Food Drug Administration(中国食品药品监管), 2023(6): 108-117. [10] WANG L, ZHANG PM, XIA B, et al.Path to Establish Medical Device Vigilance System[J]. Chinese Medical Equipment Journal(医疗卫生装备), 2024, 45(6): 83-86. [11] NMPA. Opinions of the State Drug Administration on Further Strengthening the Adverse Drug Reaction Monitoring and Evaluation System and Capacity Building[EB/OL]. (2020-07-28)[2023-09-20]. https://www.gov.cn/zhengce/zhengceku/2020-07/30/content_5531258.htm. [12] ZHAO Y, LIU WB, ZHAO YF, et al.Applicability of Patient Registry Research to Regulation of Medical Devices[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(4): 423-427. [13] NMPA. Opinions of the NMPA on Further Strengthening the Adverse Drug Reaction Monitoring System and Capacity Building[EB/OL]. (2020-07-28)[2022-01-06]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20200731134330152.html. [14] NMPA. The 14th Five-Year Plan for National Drug Safety and Promotion of High Quality Development[EB/OL]. (2020-12-30)[2022-01-06]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjzh/20211230192314164.html. [15] HAN K, MA SQ.The Construction of the Medical Device Vigilance System in China[J]. Chinese Journal of Medical Guide(中国医药导刊), 2025, 27(7): 666-673. [16] LI Y, BIAN RR, JIAO LL, et al.Reflections on Establishing a Medical Device Vigilance System in China Based on Post-Market Regulatory Requirements in the United States and European Union[J]. China Food Drug Administration(中国食品药品监管), 2024(2): 94-103. [17] LI D, SONG YN, WANG LG, et al.Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2025, 22(7): 780-785. [18] LI D, ZHAO Y.Roles of National Arthroplasty Registries in Post-Market Surveillance of Medical Devices[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2025, 22(6): 640-644. |